期刊文献+

氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床研究 被引量:2

Clinical Effect of Amlodipine Atorvastatin Calcium Tablets on Hypertension and Coronary Heart Disease
下载PDF
导出
摘要 目的探究氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床疗效。方法选取本院2013年2月—2014年2月收治的高血压合并冠心病患者110例,随机分为甲、乙两组,各55例。甲组患者采用氨氯地平阿托伐他汀钙片治疗,乙组患者采用硝苯地平治疗,比较两组患者的临床疗效。结果甲组总有效率为94.5%(52/55),高于乙组的83.6%(46/55),差异有统计学意义(P<0.05)。治疗后,两组患者的TC、TG、HDL-C及LDL-C均降低,且甲组均低于乙组,差异有统计学意义(P<0.05)。结论氨氯地平阿托伐他汀钙片治疗高血压合并冠心病效果显著,能有效改善患者的血压与心率,且耐受性好、不良反应小。 Objective To explore the clinical effect of amlodipine atorvastatin calcium tablets on hypertension and coronary heart disease. Methods 110 patients with hypertension and coronary heart disease in our hospital from February 2013 to February 2014 were selected, and then they were randomly divided into A group and B group, 55 cases in each. A group was treated with amlodipine atorvastatin calcium tablets, B group was treated with nifedipine. The elinical effect between the two groups was compared. Results The total effective rate of A group was 94. 5% (52/55), was higher than that of B group of 83.6% (46/55), the difference was statistically significant (P 〈 0. 05 ). After treatment, TC, TG, HDL- C and LDL -C of two groups were reduced, and those of A group were lower than B group, the difference was statistically significant ( P 〈 0. 05). Conclusion Amlodipine atorvastatin calcium tablets has remarkable clinical effect on hypertension and coronary heart disease, which can effectively improve the patients'blood pressure and heart rate, has better tolerance and less adverse reac- tions.
作者 彭晓燕
出处 《临床合理用药杂志》 2014年第27期3-4,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 高血压 冠心病 氨氯地平 阿托伐他汀钙片 治疗结果 Hypertension Coronary disease Amlodipine Atorvastatin calcium tablets Treatment outcome
  • 相关文献

二级参考文献23

  • 1王鸿懿.高血压合并稳定型冠心病患者中钙拮抗剂的应用[J].中国社区医师,2006,22(13):24-25. 被引量:13
  • 2陈新石.高血压患者控制高血压同时降低胆固醇(联合使用络活喜和立普妥)可降低冠心病死亡和心肌梗死发作的风险[J].中华医学杂志,2007,87(10):717-717. 被引量:23
  • 3孔灵芝,胡盛寿.中国心血管病报告2006[M].北京:中国大百科全书出版社,2008.
  • 4Baigent C,Keech A,Keamey P M,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meal-analysis of data from 90,056 participants in 14 rendomiscd trials of stains [J]. Lancet, 2005,366~ 1267 1278.
  • 5Chapman R H,Benner J S,Petrilla A A,et al. Predictors of adhemaee with antihypertensive and lipid-lowering therapy[J]. Arch Intern Med,2005,165 : 1147-1152.
  • 6Patel B V, Leslie R S, Thiebaud P, et al. Adherence with singlepill amlodipine/atorvastain vs a two pill regimen [J]. Vase Health Risk Manag,2008,4(3):673-681.
  • 7Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG- CoA reductase inhibitors on blood pressure in patients with es- sential hypertension and primary byperchol esterolemia[J]. Hypertension, 1999,34(6) : 1281-1286.
  • 8《中国高血压防治指南》修订委员会.中国高血压防治指南2010年修订版[M].北京:人民卫生出版社,2010.
  • 9SEVER P S, DAHLOF B, POULTER N R, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentra- tions, in the Anglo - Scandinavian Cardiac Outcomes Trim - Lipid Lowering Arm ( ASCOT - LIA ) : a muhicentre randomized con- trolled triM[J]. Lancet, 2003, 361(9364) : 1149 -1158.
  • 10程龙献,魏宇淼.积极降压与联合降脂治疗策略在高危高血压患者治疗中的价值[J].临床心血管病杂志,2008,24(10):721-722. 被引量:26

共引文献415

同被引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部